Cargando…

Sodium-Dependent Glucose Transporter 1 (SGLT1) Stabled by HER2 Promotes Breast Cancer Cell Proliferation by Activation of the PI3K/Akt/mTOR Signaling Pathway in HER2+ Breast Cancer

Aerobic glycolysis is a hallmark of tumor cells. SGLT1 plays a vital role in glucose metabolism. However, whether SGLT1 could promote cell growth and proliferation in breast cancer remains unclear. Here, we investigated the expression of SGLT1 in breast cancer and examined its role in malignant beha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jinlu, Ji, Hongfei, Niu, Xingjian, Yin, Lei, Wang, Yiran, Gu, Yucui, Li, Dongbo, Zhang, Han, Lu, Minghui, Zhang, Fengxia, Zhang, Qingyuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7191406/ https://www.ncbi.nlm.nih.gov/pubmed/32377271 http://dx.doi.org/10.1155/2020/6103542

Ejemplares similares

Tumor‐associated macrophages secrete CC‐chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer
por: Li, Dongbo, et al.
Publicado: (2019)

Sodium/glucose cotransporter 1-dependent metabolic alterations induce tamoxifen resistance in breast cancer by promoting macrophage M2 polarization
por: Niu, Xingjian, et al.
Publicado: (2021)

Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer
por: Holloway, Ryan W., et al.
Publicado: (2021)

HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer
por: Zhang, Han, et al.
Publicado: (2021)

Serum amyloid A 1 induces suppressive neutrophils through the Toll‐like receptor 2–mediated signaling pathway to promote progression of breast cancer
por: Niu, Xingjian, et al.
Publicado: (2022)

Enhancing Fatty Acid Catabolism of Macrophages Within Aberrant Breast Cancer Tumor Microenvironment Can Re-establish Antitumor Function
por: Gu, Yucui, et al.
Publicado: (2021)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Photothermal therapeutic application of gold nanorods-porphyrin-trastuzumab complexes in HER2-positive breast cancer
por: Kang, Xinmei, et al.
Publicado: (2017)

Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients
por: Cao, Guo-dong, et al.
Publicado: (2017)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Corrigendum: Photothermal therapeutic application of gold nanorods-porphyrin-trastuzumab complexes in HER2-positive breast cancer
por: Kang, Xinmei, et al.
Publicado: (2017)

MiR-98-5p/IGF2 Axis Influence Herceptin Sensitivity through IGF1R/HER2 Heterodimer Formation and AKT/mTOR Signal Pathway in HER2 Positive Breast Cancer
por: Zhang, Mingliang, et al.
Publicado: (2021)

Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer
por: Sobhani, Navid, et al.
Publicado: (2018)

Carvacrol: An In Silico Approach of a Candidate Drug on HER2, PI3Kα, mTOR, hER-α, PR, and EGFR Receptors in the Breast Cancer
por: Herrera-Calderon, Oscar, et al.
Publicado: (2020)

The Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere Copy Number in HER2 Fish Equivocal Breast Carcinomas
por: Ji, Hongfei, et al.
Publicado: (2015)

Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
por: Chen, Zhaoxu, et al.
Publicado: (2023)

Delphinidin induced protective autophagy via mTOR pathway suppression and AMPK pathway activation in HER-2 positive breast cancer cells
por: Chen, Jingyao, et al.
Publicado: (2018)

FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis
por: Chen, Shinan, et al.
Publicado: (2018)

Development of Electrochemical Immunosensors for HER-1 and HER-2 Analysis in Serum for Breast Cancer Patients
por: Wignarajah, Shayalini, et al.
Publicado: (2023)

Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations
por: Tian, Hao, et al.
Publicado: (2023)

LncRNA ST7-AS1 is a Potential Novel Biomarker and Correlated With Immune Infiltrates for Breast Cancer
por: Zhang, Ziwen, et al.
Publicado: (2021)

Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer
por: du Rusquec, Pauline, et al.
Publicado: (2020)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors
por: Floros, Konstantinos V., et al.
Publicado: (2021)

Can HER2 1+ Breast Cancer Be Considered as HER2-Low Tumor? A Comparison of Clinicopathological Features, Quantitative HER2 mRNA Levels, and Prognosis among HER2-Negative Breast Cancer
por: Shu, Lan, et al.
Publicado: (2022)

Improving HER2 testing reproducibility in HER2-low breast cancer
por: Sajjadi, Elham, et al.
Publicado: (2022)

HER2/positive and HER2/low in inflammatory breast cancer recurrence
por: Movchan, Oleksii Volodimirovich, et al.
Publicado: (2022)

Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer
por: Kim, Yun Gyoung, et al.
Publicado: (2017)

Analyzing the multi-target pharmacological mechanism of folium Artemisia argyi acting on breast cancer: a network pharmacology approach
por: Song, Ying, et al.
Publicado: (2022)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
por: Novillo, Apolonia, et al.
Publicado: (2023)

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer
por: de Melo Gagliato, Debora, et al.
Publicado: (2016)

Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
por: Tarantino, P., et al.
Publicado: (2023)

Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
por: Stanowicka-Grada, Malwina, et al.
Publicado: (2023)

Clinical implications of the coexpression of SRC1 and NANOG in HER-2-overexpressing breast cancers
por: Jin, Chengyan, et al.
Publicado: (2016)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

Adjuvant therapy of HER2(+ )breast cancer
por: Winer, EP
Publicado: (2009)

Immunotherapy for HER-2 positive breast cancer
por: Yang, Tingting, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6qp3fppaps6uk9cig2dlls4jjl